Achieve Life Sciences, Inc. (ACHV): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACHV Stock Price Chart Interactive Chart >
ACHV Price/Volume Stats
| Current price | $6.90 | 52-week high | $10.09 |
| Prev. close | $7.10 | 52-week low | $5.62 |
| Day low | $6.62 | Volume | 48,800 |
| Day high | $7.21 | Avg. volume | 72,342 |
| 50-day MA | $7.23 | Dividend yield | N/A |
| 200-day MA | $7.64 | Market Cap | 66.81M |
Achieve Life Sciences, Inc. (ACHV) Company Bio
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation aids in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Latest ACHV News From Around the Web
Below are the latest news stories about Achieve Life Sciences Inc that investors may wish to consider to help them evaluate ACHV as an investment opportunity.
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2021 Financial Results and Host Conference Call and Webcast on March 10, 2022SEATTLE and VANCOUVER, British Columbia, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will report its fourth quarter and year-end 2021 financial results and provide an update on the cytisinicline development program on Thursday, March 10, 2022, at 4:30 PM EST. To access the webcast, log |
ACHV: The Final Phase III BeginsBy John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Since Our Last Update Since our last update , Achieve Life Sciences, Inc. (NASDAQ:ACHV) announced several milestones. In January, Achieve’s pivotal, Phase III ORCA-2 1 trial had its last subject, last follow up, and the confirmatory Phase III ORCA-3 trial was initiated. In addition, Achieve hosted a key opinion leader panel |
Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement AwardSEATTLE and VANCOUVER, British Columbia, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has expanded its Clinical Operations Team with the hiring of a Director of Clinical Operations. Achieve’s Board of Directors approved the new employment inducement grant of stock options |
Achieve Life Sciences Announces Participation in February Investor ConferencesSEATTLE and VANCOUVER, British Columbia, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating in the Winter Wonderland Best Ideas Virtual Investor Conference and Aegis Virtual Conference during February 2022. Winter Wonderland Best Ideas Virtual Investor Conference Date: T |
36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022RALEIGH, NC / ACCESSWIRE / January 28, 2022 / The Winter Wonderland Best Ideas Virtual Investor Conference will take place on February 8th \- 11th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.The virtual conference begins on Tuesday, February 8th, 2022, with company presentations beginning at 8:30 am Eastern Time. |
ACHV Price Returns
| 1-mo | -10.85% |
| 3-mo | -10.04% |
| 6-mo | -9.21% |
| 1-year | -24.67% |
| 3-year | -90.39% |
| 5-year | -99.13% |
| YTD | -11.31% |
| 2021 | -3.95% |
| 2020 | -23.57% |
| 2019 | -56.21% |
| 2018 | -90.97% |
| 2017 | -75.64% |
Loading social stream, please wait...